Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Counterfeiters Increasingly Target Chronic Illness - Reps. Buyer, Matheson

Executive Summary

Drugs to treat chronic conditions are increasingly being counterfeited, a problem that helps underscore the need for electronic pedigree legislation, Rep. Steve Buyer, R-Ind., said at an April 22 press conference to promote the "Safeguarding America's Pharmaceuticals Act.

You may also be interested in...



EC Considers API Regulation In Effort To Fight Counterfeit Drugs

Stricter requirements for active ingredients, a ban on repackaging, and mandatory company audits of their trading partners are on the table in the European Commission's quest for antidotes to a growing influx of counterfeit medicines

EC Considers API Regulation In Effort To Fight Counterfeit Drugs

Stricter requirements for active ingredients, a ban on repackaging, and mandatory company audits of their trading partners are on the table in the European Commission's quest for antidotes to a growing influx of counterfeit medicines

Foreign Drug Inspections Would Be Funded By Registration Fees In Draft Bill

FDA inspections of overseas drug producers would be supported by annual registration fees under a legislative "discussion draft" being circulated by House Energy and Commerce Committee Chairman John Dingell, D-Mich

Related Content

UsernamePublicRestriction

Register

PS049552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel